Stock DZ
19.02.2018 kl 14:57

have sent an email to DNB markets including a couple of their Pharma analysts, wondering if they are working on PCI biotech case with reference to Arctic securities target price due to share price development. I think it is only fair for a customer to directly ask the question that can help him to assess his investment case with the brokerage house he is trading through.

It will be interesting to at least see a repl
Redigert 19.02.2018 kl 14:59 Arkivert